Summit Moving Lead Drugs with Wellcome Trust Award
By Nuala Moran
Wednesday, October 24, 2012
LONDON Summit plc is making headway with its two lead programs, winning a £4 million (US$6.42 million) translation award from the Wellcome Trust for clinical trials of SMT19969, a narrow-spectrum antibiotic for treating Clostridium difficile infections, and starting Phase II development of SMT-C1100, a treatment for Duchenne's muscular dystrophy (DMD).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.